Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia

See allHide authors and affiliations

Science  28 Nov 2008:
Vol. 322, Issue 5906, pp. 1377-1380
DOI: 10.1126/science.1164266


Most children with acute lymphoblastic leukemia (ALL) can be cured, but the prognosis is dismal for the minority of patients who relapse after treatment. To explore the genetic basis of relapse, we performed genome-wide DNA copy number analyses on matched diagnosis and relapse samples from 61 pediatric patients with ALL. The diagnosis and relapse samples typically showed different patterns of genomic copy number abnormalities (CNAs), with the CNAs acquired at relapse preferentially affecting genes implicated in cell cycle regulation and B cell development. Most relapse samples lacked some of the CNAs present at diagnosis, which suggests that the cells responsible for relapse are ancestral to the primary leukemia cells. Backtracking studies revealed that cells corresponding to the relapse clone were often present as minor subpopulations at diagnosis. These data suggest that genomic abnormalities contributing to ALL relapse are selected for during treatment, and they point to new targets for therapeutic intervention.

Despite cure rates for pediatric ALL exceeding 80% (1), treatment failure remains a formidable problem. Relapsed ALL ranks as the fourth most common childhood malignancy and has an overall survival rate of only 30% (2, 3). Important biological and clinical differences have been identified between diagnostic and relapsed leukemic cells, including the acquisition of new chromosomal abnormalities, gene mutations, and reduced responsiveness to chemotherapeutic agents (47). However, many questions remain about the molecular abnormalities responsible for relapse, as well as the relationship between the cells giving rise to the primary and recurrent leukemias in individual patients.

Single-nucleotide polymorphism (SNP) arrays have enabled genome-wide analyses of DNA CNAs and loss of heterozygosity (LOH) in cancer and have provided important insights into the pathogenesis of newly diagnosed ALL. We previously reported multiple recurring somatic CNAs in genes encoding transcription factors, cell cycle regulators, apoptosis mediators, lymphoid signaling molecules, and drug receptors in B-progenitor and T-lineage ALL (B-ALL and T-ALL) (8, 9). To gain insights into the molecular lesions responsible for ALL relapse, we have now performed genome-wide CNA and LOH analyses on matched diagnostic and relapse bone marrow samples from 61 pediatric ALL patients (table S1). These samples included 47 B-ALL and 14 T-ALL cases (10). Samples were flow-sorted to ensure at least 80% tumor cell purity before DNA extraction (fig. S1). DNA copy number and LOH data were obtained using Affymetrix SNP 6.0 (47 diagnosis-relapse pairs) or 500K arrays (14 pairs). Remission bone marrow samples were also analyzed for 48 patients (table S1).

These analyses identified a mean of 10.8 somatic CNAs per B-ALL case and 7.1 CNAs per T-ALL case at diagnosis (table S4 and figs. S2 and S4). Of the B-ALL cases at diagnosis, 48.9% had CNAs in genes known to regulate B-lymphoid development, including PAX5 (N = 12), IKZF1 (N = 12), EBF1 (N = 2), and RAG1/2 (N = 2) (tables S5, S6, and S9). Deletion of CDKN2A/B was present in 36.2% of B-ALL and 71.4% T-ALL cases, and deletion of ETV6 was present in 11 B-ALL cases. We also identified novel CNAs involving ARID2, which encodes a member of a chromatin-remodeling complex (11); the cyclic adenosine monophosphate–regulated phosphoprotein ARPP-21; the cytokine receptor genes IL3RA and CSF2RA (fig. S3); and the Wnt/β-catenin pathway genes CTNNB1, WNT9B, and CREBBP (tables S5 and S6).

Although evidence for clonal evolution and/or selection at relapse has been reported (4, 6, 7, 1221), we observed a striking degree of change in the number, extent, and nature of CNAs between diagnosis and relapse in paired samples of ALL. A significant increase in the mean number of CNAs per case was observed in relapse B-ALL samples (10.8 at diagnosis versus 14.0 at relapse, P = 0.0005), with the majority being additional regions of deletion (6.8 deletions per case at diagnosis versus 9.2 deletions per case at relapse, P = 0.0006; 4.0 gains per case at diagnosis versus 4.8 gains per case at relapse, P = 0.03; table S4 and fig. S4). By contrast, no significant changes in lesion frequency were observed in T-ALL (table S4).

The majority (88.5%) of relapse samples harbored at least some of the CNAs present in the matched diagnosis sample, indicating a common clonal origin (table S5 and fig. S5); however, 91.8% exhibited a change in the pattern of CNAs from diagnosis to relapse (table S7). Of these, 34% acquired new CNAs, 12% showed loss of lesions present at diagnosis, and 46% both acquired new lesions and lost lesions present at diagnosis. In 11% of relapsed samples (three B-ALL and four T-ALL cases), all CNAs present at diagnosis were lost at relapse, raising the possibility that the relapse represents the emergence of a second unrelated leukemia. One case (BCR-ABL-SNP-15) retained the same translocation at relapse, indicating a common clonal origin. In four cases, lack of similarity of the patterns of deletion at immunoglobulin (Ig) and T cell antigen receptor (TCR) gene loci, or lack of deletions at these loci, suggested that relapse represented the emergence of a distinct leukemia (see below and figs. S6 and S7). For all other relapse cases (86%), analysis of Ig and TCR deletions demonstrated a clonal relationship between diagnostic and relapse samples (table S21 and fig. S6).

The genes most frequently affected by CNAs acquired at relapse were CDKN2A/B, ETV6, and regulators of B cell development (Table 1, Fig. 1, tables S8 to S18, and fig. S8). Sixteen B-ALL and two T-ALL cases acquired new CNAs of CDKN2A/B, 10 of which lacked CDKN2A/B deletions at diagnosis (Fig. 1, A and B, and tables S17 and S18). The CDKN2A/B deletions acquired at relapse were biallelic in 70% of cases, resulting in a complete loss of expression of all three encoded proteins: INK4A (p16), ARF (p14), and INK4B (p15). Deletion of ETV6, a frequent abnormality at diagnosis in ETV6-RUNX1 B-ALL (8, 19), was also common in relapsed ALL, being identified in 11 cases (10 B-ALLs and one T-ALL) with only one case ETV6-RUNX1–positive (fig. S8). Mutations of genes regulating B cell development are common at diagnosis in B-ALL (8), and additional lesions in this pathway were observed at relapse, with a number of cases acquiring multiple hits within the pathway (table S9). Four cases lacked CNAs in this pathway at diagnosis but acquired deletions in PAX5 (N = 1), IKZF1 (N = 2), or TCF3 (N = 1) at relapse. Eleven cases with CNAs in this pathway at diagnosis acquired additional lesions at relapse, most commonly IKZF1 (five cases), IKZF2 (two cases), and IKZF3 (one case) (figs. S9 and S10). New CNAs were also observed in PAX5 (N = 3), TCF3 (N = 3), RAG1/2 (N = 2; figs. S9 and S10), and EBF1 (N = 1; fig. S9). CNAs involving genes that encode regulators of lymphoid development were also observed in four T-ALL relapse samples, but these involved the early lymphoid regulators IKZF1 (N = 2), IKZF2 (N = 1), and LEF1 (N = 2; table S9), rather than B lineage–specific genes such as PAX5 and EBF1.

Fig. 1.

Deletions of CDKN2A/B and lesion-specific backtracking in relapsed ALL. (A) Log2 ratio Affymetrix SNP 6.0 copy number data (median smoothed with a window of five markers; blue is deletion and red is gain) of chromosome 9p flanking CDKN2A/B for nine representative cases showing new or more extensive deletions at this locus at relapse. Deletions in selected cases were confirmed by quantitative genomic PCR (table S17). (B) Coverage of the locus for one case. Each vertical red line represents the genomic position and log2 ratio copy number of an individual marker. This case has acquired a homozygous deletion involving exon 2 of CDKN2B and all of CDKN2A at relapse. (C to H) Backtracking of CNAs by lesion-specific genomic PCR assays in ALL [(C) to (E), ADD3; (F) to (H), C20orf94]. Log2 ratio copy number heat maps for diagnosis and relapse samples are shown in (C) and (F); genomic locations of SNP probes and regions of deletion are shown in (D) and (G). In (E) and (H), PCR for each lesion was performed for diagnosis, relapse, and (where available) germline DNA samples. In each case, a CNA-specific PCR product was observed at diagnosis as well as relapse, indicating that each CNA was present at diagnosis.

Table 1.

Targets of relapse-acquired CNAs in ALL, ranked in order of frequency.

View this table:

A number of other less frequent CNAs previously detected in diagnostic ALL samples (8) were also observed as new lesions at relapse, including CNAs of ADD3, ARPP-21, ATM, BTG1, CD200/BTLA, FHIT, KRAS, IL3RA/CSF2RA, NF1, PTCH, TBL1XR1, TOX, WT1, NR3C1, and DMD (table S8 and fig. S11). Progression of intrachromosomal amplification of chromosome 21, a poor prognostic marker in childhood ALL (22), was also observed in two B-ALL cases (fig. S12). In addition, relapsed T-ALL was remarkable for the loss and acquisition of sentinel lesions, including the loss of NUP214-ABL1 in one case, and the acquisition of NUP214-ABL1, LMO2, and MYB amplification (one case each) at relapse (8, 2325) (table S8 and fig. S13).

In addition to defining CNAs, we performed an analysis of regions of copy-neutral LOH (CN-LOH) that can signify mutated, reduplicated genes. CN-LOH acquired at relapse was identified in only 15B-ALL and three T-ALL cases (table S19). The most common region involved was chromosome 9p (N = 8), which in each case contained a homozygous CDKN2A/B deletion consistent with reduplication of a hemizygous CDKN2A/B deletion.

To determine which biologic pathways were most frequently targeted by relapse-acquired CNAs, we categorized each gene contained within altered genomic regions into one or more of 148 biologic pathways. The pathways were then assessed for their frequency of involvement by CNAs across the data set with the use of Fisher's exact test (10). This analysis identified cell cycle regulation and B cell development as the most common pathways targeted at relapse (table S20).

There was a clear clonal relationship between the diagnosis and relapse ALL samples in most cases (93.6% of B-ALL and 71.4% of T-ALL cases). This suggests that the relapse-associated CNAs either (i) were present at low levels at diagnosis and selected for at relapse, or (ii) were acquired as new genomic alterations after initial therapy. To explore these possibilities, we mapped the genomic breakpoints of several CNAs acquired at relapse (ADD3, C20orf94, DMD, ETV6, IKZF2, and IKZF3) and developed lesion-specific polymerase chain reaction (PCR) assays. Evidence of the relapse clone was detected in 7 of 10 diagnosis samples analyzed (Fig. 1, C to H, and figs. S14 and S15). Thus, the relapse clone is frequently present as a minor subpopulation at diagnosis.

By carefully analyzing the changes in CNAs between matched diagnostic and relapse samples, we were able to map their evolutionary relationship (Fig. 2). In a minority of cases, “relapse” is a misnomer, as no CNAs were shared by the diagnostic and relapse clones. The recurrent disease in these cases represents either a secondary leukemia or a leukemia arising from an ancestral clone that lacks any of the CNAs present in the diagnosis leukemia. In 8% of the cases, there were no differences in CNAs between the diagnostic and relapse clones, whereas in 34% of the cases, relapse represented clonal evolution of the diagnosis leukemic populations. Remarkably, in about half of the cases, the relapse clone was derived from an ancestral, prediagnosis leukemic precursor cell and not from the clone predominating at diagnosis. One illustrative case (Other-SNP-29) had two relapse-acquired deletions (ETV6 and DMD), only one of which was present in the diagnostic sample as a minor clone (ETV6, fig. S15), indicating that these lesions were acquired at different stages of evolution of the relapse clone. This case provides unequivocal evidence of a common ancestral clone that gave rise to the major clone at diagnosis, and to a second clone that was present as a minor population at diagnosis but acquired different genetic alterations before emerging as the relapse clone.

Fig. 2.

Clonal relationship of diagnosis and relapse samples in ALL. The majority of relapse cases have a clear relationship to the diagnosis leukemic clone, either arising through the acquisition of additional genetic lesions or, more commonly, arising from an ancestral (prediagnosis) clone. In the latter scenario, the relapse clone acquires new lesions while retaining some but not all of the lesions found in the diagnostic sample. Lesion-specific backtracking studies revealed that in most cases the relapse clone exists as a minor subclone within the diagnostic sample before the initiation of therapy. In only a minority of ALL cases does the relapse clone represent the emergence of a genetically distinct and thus unrelated second leukemia.

These results complement those of previous studies examining individual genetic loci in relapsed ALL (6, 14, 16, 20, 21, 2628) and provide important insights into the spectrum of genetic lesions that underlie this process. Although our data are limited to a single class of mutations (CNAs), they show that no single genetic lesion or alteration of a single pathway is responsible for relapse. Moreover, global genomic instability does not appear to be a prevalent mechanism. Instead, a diversity of mutations appear to contribute to relapse, with the most common alterations targeting key regulators of tumor suppression, cell cycle control, and lymphoid/B cell development. Notably, few lesions involved genes with roles in drug import, metabolism, export, and/or response (an exception being the glucocorticoid receptor gene NR3C1), which suggests that the mechanism of relapse is more complex than simple “drug resistance.”

The diversity of genes that are targeted by relapse-associated CNAs, coupled with the presence of the relapse clone as a minor subpopulation at diagnosis that escapes drug-induced killing, represent formidable challenges to the development of effective therapy for relapsed ALL. Nonetheless, our study has identified several common pathways that may contain rational targets against which novel therapeutic agents can be developed.

Supporting Online Material

Materials and Methods

SOM Text

Figs. S1 to S15

Tables S1 to S21


References and Notes

View Abstract

Navigate This Article